Integrated BioPharma Q3 net income falls 36% to $0.8M; revenue $15.6M

INTEGRATED BIOPHARMA INC

2022-Q3 EPS reported $0.07 revenue$42,979,000

Q3 revenue $15.6M, down 8.4% YoY from $17.1M; operating income $1.0M vs $1.7M.
Net income $0.8M ($0.03 diluted EPS) vs $1.2M ($0.04) in prior-year quarter.
Nine-month revenue $43.0M, down 7.6%; net income $2.3M vs $3.5M.
Revenue decline attributed to normalization of customer safety stock from COVID-19 pandemic.
Two largest contract manufacturing customers still represent ~91% of total revenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.